This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Frederick T. Fraunfelder, MD
Portland, Ore

Arch Ophthalmol. 1988;106(8):1029.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—In a recent correspondence, the misuse of eye drops due to interchanged caps was presented.¹ The authors suggested a system for color-coding the bottle caps and labels of topical ophthalmic medications to decrease the incidence of confusion with similar bottles and the possibility of inadvertently misusing medications. This has been a concern of the Committee of Drugs of the American Academy of Ophthalmology for many years. With support from the Food and Drug Administration, the academy has been successful in receiving commitments from several major manufacturers of eye medications, including Alcon Pharmaceuticals, Fort Worth, Tex; Allergan Pharmaceuticals, Irvine, Calif; IOLab Pharmaceuticals, Claremont, Calif; and Merck Sharpe & Dohme, West Point, Pa, to implement such a color-coding standard for major therapeutic categories. With the help of others in the pharmaceutical industry, it is the intent of these manufacturers to implement the following drug-packaging standards for eye drop . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?